Amicus reports FY2025 results as BioMarin merger deal proceeds

Amicus Therapeutics filed audited consolidated financial statements for fiscal year 2025 as part of an 8-K/A tied to BioMarin Pharmaceutical's acquisition of the company. On December 19, 2025, the Company entered into a Merger Agreement with BioMarin and its wholly owned acquisition subsidiary, and under the terms of that agreement, if the transaction is completed, BioMarin's acquisition subsidiary will merge into Amicus, with Amicus continuing as a surviving corporation and wholly owned subsidiary of BioMarin.¹ Under the deal, shares of Amicus common stock outstanding before closing will be cancelled and turned into a right to cash payment of $14.50 per share, and once the merger closes, Amicus stock will no longer trade publicly.¹

Financially, Amicus described itself as a global biotechnology company focused on rare diseases, with two marketed therapies: Galafold for Fabry disease and Pombiliti plus Opfolda for late-onset Pompe disease.¹ For the year, total net product sales reached $634.2 million, up from $528.3 million in 2024 and $399.4 million in 2023, according to the disaggregated sales table, with Galafold sales totaling $521.7 million in 2025 and Pombiliti plus Opfolda sales rising to $112.5 million from $70.2 million in 2024.¹

Net loss attributable to common stockholders narrowed to $27.1 million in 2025 from $56.1 million in 2024 and $151.6 million in 2023.¹ Wait, that citation is wrong; correcting: The Company had an accumulated deficit of $2.8 billion as of December 31, 2025.¹ Excluding the pending merger's impact, the Company said its current cash position and expected revenues are sufficient to fund operations and ongoing research programs for at least the next 12 months.¹

Separately, on April 30, 2025, Amicus signed a licensing deal with Dimerix Bioscience giving it exclusive U.S. commercialization rights to Dimerix's late-stage drug candidate DMX-200, aimed at treating Focal Segmental Glomerulosclerosis and other conditions.¹